4th Annual Cell Engager Summit | May 24-26 | Boston, MA
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical […]
T-cell
Next Generation CAR-TCR Summit
The cell therapy field is showing no signs of slowing down, with huge investment and excitement around next generation products and their clinical validation in solid tumour […]
Repertoire Collaborates with Yale University to Identify Novel Antigen and T- Cell Receptor for Multiple Sclerosis
Shots: Repertoire and Yale University collaborated to understand the immunological causes of MS by identifying the specificity of various subsets of T cells The focus […]
Cell-Mediated Therapies for Infectious Disease Summit
In the fight against emerging coronavirus variants and spike mutations, the need for long-lasting immunity is greater than ever. This is why the time is […]
2nd TCR-based Therapies Summit
The 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density and binding affinity for solid […]
Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology
Shots: Janux to receive up to $500.5M/ target as upfront and milestones along with royalties on sales of product emerges from the collaboration, making a […]
Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda
Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while […]
Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19
Shots: The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 […]
